Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to Denosumab

Title: Successful Intravascular Correction of Intratumoral Pseudoaneurysm by Erosion of the Aorta in a Patient with Thoracic Giant Cell Tumor of Bone Responding to Denosumab
Authors: Natalia M. P. Fraile; Diego Toloi; Ceci O. Kurimori; Adriana R. B. Matutino; Alberto Codima; Veridiana P. Camargo; Olavo Feher; Rodrigo R. Munhoz
Source: Case Reports in Oncological Medicine, Vol 2015 (2015)
Publisher Information: Wiley
Publication Year: 2015
Collection: Directory of Open Access Journals: DOAJ Articles
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282
Description: Giant cell tumor of bone (GCT) is a rare, locally aggressive neoplasm characterized by the presence of giant cells with osteoclast activity. Its biology involves the overexpression of the Receptor Activator of Nuclear Factor kB Ligand (RANKL) by osteoclast-like giant cells and tumor stromal cells, which has been shown to be an actionable target in this disease. In cases amenable to surgical resection, very few therapeutic options were available until the recent demonstration of significant activity of the anti-RANK-ligand monoclonal antibody denosumab. Here we present a case of a patient with advanced GCT arising in the spine, recurring after multiple resections and embolization. Following initiation of denosumab, which resulted in unequivocal clinical improvement, computed tomography of the chest done for reassessment purposes revealed an intratumoral pseudoaneurysm by erosion of the aorta, further corrected by endovascular approach and stent placement. Patient had an unremarkable recovery from the procedure and continued benefit from therapy with denosumab and remains on treatment 24 months after the first dose.
Document Type: article in journal/newspaper
Language: English
Relation: http://dx.doi.org/10.1155/2015/626741; https://doaj.org/toc/2090-6706; https://doaj.org/toc/2090-6714; https://doaj.org/article/387c0fc7b0a9440db4494680f19a31f3
DOI: 10.1155/2015/626741
Availability: https://doi.org/10.1155/2015/626741; https://doaj.org/article/387c0fc7b0a9440db4494680f19a31f3
Accession Number: edsbas.68E99A3F
Database: BASE